Skip to content
Open access

Circulating Microbial DNA as a Potential Cancer Biomarker: Technical Challenges and Controlled Evaluation

Aug 2026 · bioRxiv · 0 citations · 17 references
Biology

TL;DR

Much of the apparent cmDNA structure, including its agreement with a published cancer-microbiome catalog, is explained by base composition and reference-database architecture rather than authentic biology, and short-read k-mer pipelines cannot separate the two on their own.

Abstract

Background Circulating microbial DNA (cmDNA) has been proposed as a non-invasive cancer biomarker, but most evidence comes from cancer-sequencing datasets not designed for microbial analysis and lacking contamination controls. Whether reported signatures reflect biology or artifact is unclear in low-biomass specimens, where standard taxonomic pipelines are prone to systematic error. Methods In a tightly controlled pilot study of metastatic castration-resistant prostate cancer, we profiled plasma cell-free DNA (cfDNA) and buffy-coat genomic DNA (gDNA) from two patients and two healthy volunteers alongside mock blood-draw and reagent controls, each with and without host-DNA depletion. Reads were classified with Kraken2/Bracken and, independently, with the marker-gene classifier MetaPhlAn. As informatics controls, reads were per-base shuffled to randomize nucleotide order while preserving read length and guanine-cytosine (GC) content, and purely synthetic reads were generated from a four-base process matched only to an aggregate GC target; both were classified identically. Genus abundances were regressed against Kraken2 database k-mer representation and against GC content. Results Across 40 samples, Kraken2 reported several thousand genera, samples clustered by specimen type in principal-coordinate analysis (PCoA), and pooled genus counts correlated strongly with a published cancer-microbiome catalog (The Cancer Genome Atlas lung adenocarcinoma, TCGA-LUAD; Spearman ρ = 0.81 over 282 shared genera), a pattern readily interpreted as biological signal. However, these observations were also made in per-base shuffling, which preserves GC content and length but destroys all biological sequence: shuffled reads were still abundantly classified, still clustered by specimen type, and still correlated with the catalog (ρ ≈ 0.7), as did every sample group, including pure reagent controls. Genus counts scaled tightly with each genus’s k-mer representation in the Kraken2 database on real (r² = 0.74) and shuffled (r² = 0.85) reads, and the same dependence appeared in the independent published cohort. Purely synthetic reads carrying no information beyond an aggregate GC target reproduced much of the cross-cohort agreement (synthetic TCGA-LUAD ρ = 0.61 versus 0.81 for real reads; significant in 27 of 33 TCGA cancers), and replicate shuffles of a low-GC versus a high-GC plasma sample, for which the true difference is zero, produced spurious significant differences in about 46% of genera. Regressing observed counts against the shuffled baseline left 23 genera above the artifact floor at 5% false discovery rate (FDR), nearly all known kit contaminants, control-enriched viruses, or very-low-abundance taxa; a four-criterion validity filter reduced thousands of Kraken2 genera to a single defensible candidate, Klebsiella. Conclusions Much of the apparent cmDNA structure, including its agreement with a published cancer-microbiome catalog, is explained by base composition and reference-database architecture rather than authentic biology, and short-read k-mer pipelines cannot separate the two on their own. We find little positive evidence of an authentic circulating microbial signal, though our small sample cannot prove its absence. To limit false discovery in low-biomass metagenomics, we recommend specimen-matched negative controls, corroboration with a conservative second classifier, per-base shuffling (with GC-matched synthetic reads as a stricter floor), and GC-aware analysis. Graphical Abstract Pipeline pitfalls in blood microbial-DNA assays. cmDNA from low-biomass blood is vulnerable to three errors across the workflow (collection, processing, library preparation and sequencing, informatics): environmental (non-blood) contamination, kit and reagent contamination, and taxonomic misclassification. The corresponding safeguards are mock and specimen-matched negative controls, a literature sweep for known contaminants, and corroboration of k-mer output with a marker-gene classifier and a shuffle-based artifact control.

Read PDF

Similar papers

Open access Aug 2026

Metagenomic profiling of blood-associated microbial DNA signatures in leukemia-associated febrile neutropenia

These findings support cautious reporting of patient-enriched microbial DNA and ARG signals rather than inference of a resident blood microbiome or clinical resistance phenotype, and identify a subset of microbial DNA and ARG signals that remained detectable under increasingly stringent control criteria while distingui...

Ming Zhang, Lan He, Hua-Ping Xin et al. · 0 citations
Open access Aug 2026

Circulating blood microbiome biomarkers as liquid biopsy in breast cancer

The findings support liquid microbiopsy as a complementary extension of liquid biopsy but must be considered as exploratory, and warrant multicenter validation in larger independent cohorts with standardized pre-analytics and low-biomass controls.

W. Jacot, L. Cayrefourcq, C. Dunyach-Rémy et al. · 0 citations
Review Open access Jul 2026

Non-Coding RNAs in Cancer Liquid Biopsy: From Regulatory Networks to Functional Biomarkers for Precision Oncology

It is proposed that ncRNAs should not be viewed as alternatives to ctDNA, but as potential functional biomarkers that can link tumor genotype, regulatory state, and clinical phenotype within integrated multi-analyte precision oncology.

Salvatore Pernagallo, Veronica Tisato, Donato Gemmati · 1 citation
Review Open access Sep 2026

Circulating Tumor DNA in Breast Cancer: A Liquid Biopsy Revolution for Non-Invasive Genomic Profiling and Clinical Decision-Making

Continuous technological innovation, prospective multicenter validation, standardized testing protocols, and evidence-based clinical guidelines are essential to fully integrate ctDNA into routine precision breast cancer care.

E. I. Obeagu, C. Okafor · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.